Journals / Retina-Vitreus / 2008 / Cilt: 16 - Sayı: 3

Systemic risk factors in branch retinal vein occlusion

Retina ven dal tıkanıklığında sistemik risk faktörleri

Pages
218–221
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Known risk factors for developing BRVO such as hypertension, hyperhomocysteinemia, hyperlipidemia and higher blood viscosity are thought to be effective in our patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of this study is to investigate the possible risk factors in patients with branch retinal vein occlusion (BRVO).
📊
Key Findings & Data:Materials and Methods: Twenty-four patients with BRVO and an age and sex-matched control group of 48 people without a history of retinal vascular diseases and systemic diseases were included in this study.
💡
Conclusion & Impact:Conclusion: Known risk factors for developing BRVO such as hypertension, hyperhomocysteinemia, hyperlipidemia and higher blood viscosity are thought to be effective in our patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Retinal ven tıkanıklığı · Kan hücresi sayımı · Homosistein

Abstract

Purpose: The aim of this study is to investigate the possible risk factors in patients with branch retinal vein occlusion (BRVO). Materials and Methods: Twenty-four patients with BRVO and an age and sex-matched control group of 48 people without a history of retinal vascular diseases and systemic diseases were included in this study. The 24 patients with BRVO were asked about any previous history of systemic diseases. The serum homocysteine, total cholesterol, trigliseride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), white blood cell, hemoglobin, hematocrit and platelet levels were measured in all patients and control group. Results: Hypertension was detected in 75% of the patients. The serum homocystein, trigliseride and hematocrit levels were found to be significantly higher in the patient group compared to the control group (p=0.002, p=0.018 and p=0.014 respectively). The serum total cholesterol, HDL, LDL, VLDL, white blood cell, hemoglobin and platelet levels were found to be similar in both the patient and control group (p>0.05). Conclusion: Known risk factors for developing BRVO such as hypertension, hyperhomocysteinemia, hyperlipidemia and higher blood viscosity are thought to be effective in our patients.

Özet

Amaç: Retina ven dal tıkanıklığı (RVDT) hastalarında olası risk faktörlerinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: RVDT tanısı almış 24 hasta ile yaş ve cinsiyet eşlemesi yapılmış, retina damar hastalığı bulunmayan ve sistemik hastalık öyküsü olmayan 48 kişilik kontrol grubu çalışmaya dahil edilmiştir. Hasta grubunda sistemik hastalıklar sorgulanmıştır. Hasta ve kontrol grubunda serum homosistein, total kolesterol, trigliserid, yüksek dansiteli lipoprotein (HDL), düşük dansiteli lipoprotein (LDL), çok düşük dansiteli lipoprotein (VLDL), beyaz küre, hemoglobin, hematokrit ve trombosit düzeyleri ölçülmüştür. Bulgular: Hasta grubunda %75 hipertansiyon öyküsü saptanmış, serum homosistein, trigliserid ve hematokrit değerlerinin de kontrol grubuna göre anlamlı düzeyde yüksek olduğu görülmüştür (sırasıyla p=0.002, p=0.018 ve p=0.014). Serum total kolesterol, HDL, LDL, VLDL, beyaz küre, hemoglobin ve trombosit değerleri hasta ve kontrol grubunda benzer bulunmuştur (p>0.05). Sonuç: RVDT gelişiminde bilinen risk faktörlerinden hipertansiyon, hiperhomosisteinemi, hiperlipidemi ve artmış kan viskozitesinin hastalarımızda etkili olabileceği düşünülmüştür.

🔖

Cite This Article

YILMAZ, A., MERCAN, M., ARGIN, M. A., TAMER, L., YILDIRIM, H., ANKARALI, H., YILDIRIM, Ö. (2008). Systemic risk factors in branch retinal vein occlusion. Retina-Vitreus, Cilt: 16 - Sayı: 3, 218–221. https://ajindex.com/articles/305200

References (18)

  1. The Eye Disease Case-control Study Group: Risk factors for branch retinal vein occlusion. Am J Ophthalmol. 1993;116:286-296
  2. Frangieh GT, Green WR, Barraquer-Somers E, et al.: Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol. 1982;100:1132-40
  3. Appiah AP, Trempe CL.: Risk factors associated with branch vs. central retinal vein occlusion. Ann Ophthalmol. 1989;21:153-157
  4. Lip PL, Blann AD, Jones AF, et al.: Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye. 1998;12:245-251
  5. Berk T, Saatçi O, Durak İ, ve ark.: Retina ven kök ve dal tıkanıklığı risk faktörleri açısından karşılaştırılması. Ret-Vit. 1995;3:81-86
  6. Uludoğan G, Güvenir M, Şen HB, ve ark.: Retina ven dal tıkanıklıklarında risk faktörleri. Ret-Vit. 1995;3:78-80
  7. Özyol E, Atmaca LS.: Retina ven tıkanıklığı. Turkiye Klinikleri J Ophthalmol. 2007;16:56-66
  8. Ray JG.: Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998;158:2101-2106
  9. Clarke R, Daly L, Robinson K, et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155
  10. Rodgers GM, Kane WH.: Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909-1916
  11. Rodgers GM, Conn MT.: Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75:895-901
  12. Hajjar KA.: Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest. 1993;91:2873-2879
  13. Loscalzo J.: The oxidant stres of hyperhomocysteinemia. J Clin I nvest. 1996;98:5-7
  14. Cahill M, Karabatzaki M, Meleady R, et al.: Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol. 2000;84:154-157
  15. Weger M, Stanger O, Deutschmann H, et al.: Hyperhomocyst(e) inemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion. Ophthalmology. 2002;109:1105-1109
  16. Hansen L, Kristensen HL, Bek T, et al.: Markers of thrombophilia in retinal vein thrombosis. Acta Ophthalmol Scand. 2000;78:523-526
  17. Vine AK.: Hyperhomocysteinemia: A risk factor for central retinal vein occlusion. Am J Ophthalmol. 2000;129:640-644
  18. Friedewald WD, Levy RI, Fredrickson DS.